R01 CA207237/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2016	1
2017	13
2018	11
2019	6
2020	9
2021	10
2022	5
2023	4
2024	1

1

Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation.

Gulla A, Morelli E, Samur MK, Botta C, Hideshima T, Bianchi G, Fulciniti M, Malvestiti S, Prabhala RH, Talluri S, Wen K, Tai YT, Richardson PG, Chauhan D, Sewastianik T, Carrasco RD, Munshi NC, Anderson KC. Gulla A, et al. Blood Cancer Discov. 2021 Sep;2(5):468-483. doi: 10.1158/2643-3230.BCD-21-0047. Epub 2021 Apr 23. Blood Cancer Discov. 2021. PMID: 34568832 Free PMC article.

2

Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma.

Du T, Song Y, Ray A, Wan X, Yao Y, Samur MK, Shen C, Penailillo J, Sewastianik T, Tai YT, Fulciniti M, Munshi NC, Wu H, Carrasco RD, Chauhan D, Anderson KC. Du T, et al. Blood. 2023 May 25;141(21):2599-2614. doi: 10.1182/blood.2022017897. Blood. 2023. PMID: 36630605 Free PMC article.

3

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma.

Yao Y, Ng JF, Park WD, Samur M, Morelli E, Encinas Mayoral J, Chyra Z, Xu Y, Derebail S, Epstein C, Nabet B, Chesi M, Gray NS, Young RA, Kwiatkowski N, Mitsiades C, Anderson KC, Lin CY, Munshi NC, Fulciniti M. Yao Y, et al. Blood. 2023 Jun 8;141(23):2841-2852. doi: 10.1182/blood.2022018885. Blood. 2023. PMID: 36877894 Free PMC article.

4

Progress and Paradigms in Multiple Myeloma.

Anderson KC. Anderson KC. Clin Cancer Res. 2016 Nov 15;22(22):5419-5427. doi: 10.1158/1078-0432.CCR-16-0625. Clin Cancer Res. 2016. PMID: 28151709 Free PMC article.

5

BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression.

Xing L, Wang S, Liu J, Yu T, Chen H, Wen K, Li Y, Lin L, Hsieh PA, Cho SF, An G, Qiu L, Kinneer K, Munshi N, Anderson KC, Tai YT. Xing L, et al. Clin Cancer Res. 2021 Oct 1;27(19):5376-5388. doi: 10.1158/1078-0432.CCR-21-1621. Clin Cancer Res. 2021. PMID: 34301753 Free PMC article.

6

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.

Tai YT, Cho SF, Anderson KC. Tai YT, et al. Front Immunol. 2018 Aug 10;9:1822. doi: 10.3389/fimmu.2018.01822. eCollection 2018. Front Immunol. 2018. PMID: 30147691 Free PMC article. Review.

7

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma.

Cho SF, Lin L, Xing L, Yu T, Wen K, Anderson KC, Tai YT. Cho SF, et al. Antibodies (Basel). 2017 Nov 14;6(4):18. doi: 10.3390/antib6040018. Antibodies (Basel). 2017. PMID: 31548533 Free PMC article. Review.

8

Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma.

Johnstone M, Vinaixa D, Turi M, Morelli E, Anderson KC, Gulla A. Johnstone M, et al. Cells. 2022 Aug 14;11(16):2519. doi: 10.3390/cells11162519. Cells. 2022. PMID: 36010596 Free PMC article. Review.

9

A 3D-Bioprinted Multiple Myeloma Model.

Wu D, Wang Z, Li J, Song Y, Perez MEM, Wang Z, Cao X, Cao C, Maharjan S, Anderson KC, Chauhan D, Zhang YS. Wu D, et al. Adv Healthc Mater. 2022 Apr;11(7):e2100884. doi: 10.1002/adhm.202100884. Epub 2021 Sep 23. Adv Healthc Mater. 2022. PMID: 34558232 Free PMC article.

10

The biological significance of histone modifiers in multiple myeloma: clinical applications.

Ohguchi H, Hideshima T, Anderson KC. Ohguchi H, et al. Blood Cancer J. 2018 Aug 22;8(9):83. doi: 10.1038/s41408-018-0119-y. Blood Cancer J. 2018. PMID: 30190472 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

49 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year